Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409708 · ClinicalTrials.gov registry record · Phase 2
Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT00409708 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 142 participants.
The verdict
NCT00409708, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study will assess the frequency of chromosomal abnormalities measured in circulating lymphocytes in treatment-naive children with Attention Deficit Hyperactivity Disorder (ADHD) treated for 3 months with either extended release methylphenidate or behavioral therapy.
Interventions
- BEHAVIORAL Behavior Therapy
- DRUG Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00409708
The ClinicalTrials.gov registry entry for NCT00409708 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Behavior Therapy is the first listed.
NCT00409708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00409708 about?
NCT00409708 is a clinical study titled "Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)". This study will assess the frequency of chromosomal abnormalities measured in circulating lymphocytes in treatment-naive children with Attention Deficit Hyperactivity Disorder (ADHD) treated for 3 months with either extended release methylphenidate or behavioral therapy.
What is the current status of trial NCT00409708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2006-11.
What interventions are being tested in trial NCT00409708?
The interventions under investigation include: Behavior Therapy (BEHAVIORAL), Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy (DRUG).
Who is sponsoring clinical trial NCT00409708?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.